Abstracts| Volume 46, ISSUE 6, SUPPLEMENT , S83-S84, June 2018

The Impact of Saccaromyces Boulardii to Reduce Clostridium Difficile in the Post-Acute Care Setting

      Background: Clostridium difficile infections pose significant risks to patients in the post-acute care setting, including prolonged hospitalization and increased mortality. In 2015 and 2016, the facility noted an increase of healthcare acquired Clostridium difficile cases on its long term acute care (LTAC) and skilled nursing (SNF) units. The purpose of this study was to determine whether implementing Saccaromyces boulardii, a daily probiotic supplement, for patients who were receiving intravenous (IV) antibiotics would reduce the rate of healthcare acquired Clostridium difficile cases.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect